Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-324-7933
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.09 million
Profitability
Miscellaneous
Employees169
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics Inc (NASDAQ:ACRS) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.77) by $0.05. The biotechnology company earned $5.87 million during the quarter, compared to analysts' expectations of $5.77 million. Aclaris Therapeutics had a negative return on equity of 81.40% and a negative net margin of 979.65%. View Aclaris Therapeutics' Earnings History.
When is Aclaris Therapeutics' next earnings date?
What price target have analysts set for ACRS?
4 brokerages have issued 1 year target prices for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $34.00. On average, they anticipate Aclaris Therapeutics' share price to reach $17.3333 in the next twelve months. This suggests a possible upside of 1,616.2% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.
What is the consensus analysts' recommendation for Aclaris Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.
What are Wall Street analysts saying about Aclaris Therapeutics stock?
Here are some recent quotes from research analysts about Aclaris Therapeutics stock:
- 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (8/21/2019)
- 2. Cantor Fitzgerald analysts commented, "We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50." (3/22/2019)
Has Aclaris Therapeutics been receiving favorable news coverage?
Media headlines about ACRS stock have trended positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aclaris Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Aclaris Therapeutics.
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include CytoDyn (CYDY), Acasti Pharma (ACST), Sol Gel Technologies (SLGL), Osmotica Pharmaceuticals (OSMT), American Brivision (Holding) (ABVC), XOMA (XOMA), Arcturus Therapeutics (ARCT), Chimerix (CMRX), Axovant Gene Therapies (AXGT), Axovant Sciences (AXON), GlycoMimetics (GLYC), Lexicon Pharmaceuticals (LXRX), Strongbridge Biopharma (SBBP), Aldeyra Therapeutics (ALDX) and Generex Biotechnology (GNBT).
What other stocks do shareholders of Aclaris Therapeutics own?
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)
- Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)
- Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)
- Mr. Frank Ruffo, Co-Founder & CFO (Age 53)
- Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60)
Who are Aclaris Therapeutics' major shareholders?
Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.21%), Man Group plc (4.97%), Rock Springs Capital Management LP (4.90%), Vanguard Group Inc. (4.52%), Renaissance Technologies LLC (1.70%) and D. E. Shaw & Co. Inc. (1.62%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.
Which institutional investors are selling Aclaris Therapeutics stock?
ACRS stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., AXA, Rice Hall James & Associates LLC, Cormorant Asset Management LP, Citadel Advisors LLC, BlackRock Inc., Bank of New York Mellon Corp and Morgan Stanley. View Insider Buying and Selling for Aclaris Therapeutics.
Which institutional investors are buying Aclaris Therapeutics stock?
ACRS stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Rock Springs Capital Management LP, Renaissance Technologies LLC, JPMorgan Chase & Co., Walleye Trading Advisors LLC, Walleye Trading LLC, Alambic Investment Management L.P. and Parametric Portfolio Associates LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.
How do I buy shares of Aclaris Therapeutics?
Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of ACRS stock can currently be purchased for approximately $1.01.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $41.78 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.
What is Aclaris Therapeutics' official website?
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
